Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.48
5.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Quoin Pharmaceuticals Ltd
Net Issuance of Common Stock
Quoin Pharmaceuticals Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Q
|
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
|
Net Issuance of Common Stock
$5.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Compugen Ltd
NASDAQ:CGEN
|
Net Issuance of Common Stock
$2.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-31%
|
|
|
B
|
Biolight Life Sciences Ltd
TASE:BOLT
|
Net Issuance of Common Stock
₪503k
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
-35%
|
|
Quoin Pharmaceuticals Ltd
Glance View
Quoin Pharmaceuticals Ltd. is a specialty pharmaceutical company engaged in the development of therapeutic products for the treatment of rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
See Also
What is Quoin Pharmaceuticals Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
5.5m
USD
Based on the financial report for Jun 30, 2024, Quoin Pharmaceuticals Ltd's Net Issuance of Common Stock amounts to 5.5m USD.
What is Quoin Pharmaceuticals Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-3%
Over the last year, the Net Issuance of Common Stock growth was -6%.
You don't have any saved screeners yet
